
EyePoint's stock plunges 66% after failed Phase 3 trial for wet AMD treatment.
EyePoint, Inc. announced that its Phase 3 clinical trial for DURAVYU, a treatment for wet age-related macular degeneration, failed to meet the primary endpoint. Following this announcement, EyePoint's stock price dropped over 66%, causing significant...

